CN117838854A - Stabilizer composition of antibody medicine and pharmaceutical composition - Google Patents
Stabilizer composition of antibody medicine and pharmaceutical composition Download PDFInfo
- Publication number
- CN117838854A CN117838854A CN202311817823.9A CN202311817823A CN117838854A CN 117838854 A CN117838854 A CN 117838854A CN 202311817823 A CN202311817823 A CN 202311817823A CN 117838854 A CN117838854 A CN 117838854A
- Authority
- CN
- China
- Prior art keywords
- antibody
- pharmaceutical composition
- acid
- formulation
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 68
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title abstract description 97
- 239000003381 stabilizer Substances 0.000 title abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 239000000872 buffer Substances 0.000 claims abstract description 31
- 239000003223 protective agent Substances 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 123
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 54
- 239000004475 Arginine Substances 0.000 claims description 44
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 44
- 235000009697 arginine Nutrition 0.000 claims description 44
- 235000015165 citric acid Nutrition 0.000 claims description 41
- 235000018102 proteins Nutrition 0.000 claims description 34
- 102000013691 Interleukin-17 Human genes 0.000 claims description 30
- 108050003558 Interleukin-17 Proteins 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 22
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 18
- 235000011054 acetic acid Nutrition 0.000 claims description 18
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 18
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 18
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 17
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 17
- 229930182817 methionine Natural products 0.000 claims description 17
- 235000006109 methionine Nutrition 0.000 claims description 17
- 229940068977 polysorbate 20 Drugs 0.000 claims description 17
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 15
- 229920000053 polysorbate 80 Polymers 0.000 claims description 15
- 229940068968 polysorbate 80 Drugs 0.000 claims description 14
- 150000003839 salts Chemical group 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 150000001413 amino acids Chemical group 0.000 claims description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000012931 lyophilized formulation Substances 0.000 claims description 5
- 235000011007 phosphoric acid Nutrition 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 41
- 239000007788 liquid Substances 0.000 abstract description 17
- 229940125644 antibody drug Drugs 0.000 abstract description 6
- 230000002349 favourable effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 69
- 239000000243 solution Substances 0.000 description 36
- -1 sorbitan fatty acid esters Chemical class 0.000 description 31
- 238000000034 method Methods 0.000 description 22
- 239000007853 buffer solution Substances 0.000 description 16
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 238000001542 size-exclusion chromatography Methods 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 230000003204 osmotic effect Effects 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 238000004255 ion exchange chromatography Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 229960004540 secukinumab Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000001265 Jonckheere trend test Methods 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OZBJWQQAAQSQPL-WCCKRBBISA-N acetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N OZBJWQQAAQSQPL-WCCKRBBISA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000000533 capillary isoelectric focusing Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- SLBXZQMMERXQAL-UHFFFAOYSA-M sodium;1-dodecoxy-4-hydroxy-1,4-dioxobutane-2-sulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O SLBXZQMMERXQAL-UHFFFAOYSA-M 0.000 description 1
- MWZFQMUXPSUDJQ-KVVVOXFISA-M sodium;[(z)-octadec-9-enyl] sulfate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCCOS([O-])(=O)=O MWZFQMUXPSUDJQ-KVVVOXFISA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Abstract
The invention discloses a stabilizer composition of an antibody drug and a pharmaceutical composition. The stabilizer composition of the antibody medicine contains a negatively charged buffer agent and a positively charged protein protecting agent. The pharmaceutical composition comprises: antibody class medicine and the stabilizer composition. The stabilizer composition is favorable for better stability of the antibody medicine in the liquid preparation, and ensures that the liquid preparation has lower viscosity under the condition of higher concentration of the antibody medicine.
Description
Technical Field
The invention belongs to the technical field of antibodies, and particularly relates to a stabilizer composition of an antibody drug and a pharmaceutical composition.
Background
For antibody-based drugs, the stability of their ready-to-use pharmaceutical products or liquid pharmaceutical compositions can be challenging. Antibodies, which are immunoglobulins in nature, are a protein. The marginal stability of proteins in liquid compositions often prevents long-term storage at room temperature or under refrigerated conditions. Proteins may undergo various physical and chemical reactions in solution (aggregation [ covalent and non-covalent ], deamidation, oxidation, shearing, isomerization, denaturation), leading to increased levels of degradation products and/or loss of biological activity. The safety and effectiveness of the drug are adversely affected by the by-products produced, and the development of a formulation recipe excellent in stability is very important for clinical medication.
Commercial ready-to-use liquid antibody compositions should provide sufficient physical and chemical stability of the antibody during transport and handling to ensure compliance with dosage and product safety requirements when the molecule is administered to a patient. Acceptable liquid antibody compositions must be stable and minimize protein degradation, particularly protein aggregation, to avoid serious immunogenic reactions. The composition must also have an acceptable osmotic pressure and pH for subcutaneous application and have low viscosity and injectability as a prerequisite for preparation (compounding, filtration, filling). Balancing this number of requirements is difficult, making the production of commercially viable aqueous biopharmaceutical compositions a technical challenge.
The Studies monoclonal antibody is a fully humanized monoclonal anti-IL-17A inflammatory cytokine IgG1 antibody, and through combination with IL-17A, the interaction between IL-17A and a receptor thereof is directly blocked, so that immune and inflammatory reactions are changed to achieve the treatment purpose. (active ingredient: secukinumab, studimumab) is the first global heavy-duty biological drug targeting IL-17A developed by North Corp. The stabilizer is preferably trehalose (CN 201580076632.9). Patent CN201910412754.0 prefers xylitol and sorbitol as stabilizers. Patent CN201910935046.5 prefers sucrose as a stabilizer. Patent CN201911239277.9 uses citrate buffer, sucrose, arginine, polysorbate 80 as a stabilizer composition.
Disclosure of Invention
In order to solve the above problems in the prior art, the present invention provides a stabilizer composition for antibody drugs, which comprises a negatively charged buffer and a positively charged protein protectant.
In some embodiments, the negatively charged buffer is selected from one or more of citric acid, acetic acid, phosphoric acid, succinic acid, aspartic acid, glutamic acid, lactic acid; the positively charged protein protectant is selected from one or more of arginine, lysine and histidine.
In some embodiments, the concentration of the negatively charged buffer is 5 to 100mM, preferably 5 to 50mM, more preferably 5 to 35mM, and most preferably 5 to 25mM (such as 10mM or 20 mM); the concentration of the positively charged protein protecting agent is 50-270mM, preferably 80-240mM, more preferably 100-220mM, most preferably 130-190mM (such as 150mM or 175 mM); the antibody medicine is selected from one or more of anti-human IL-17A monoclonal antibody, anti-human HER2 monoclonal antibody and anti-human TNF-alpha monoclonal antibody.
In another aspect, the invention discloses an antibody pharmaceutical composition comprising a negatively charged buffer, a positively charged protein protectant, and an antibody, wherein:
the negatively charged buffer is an acid substantially free of its salt form, the acid being selected from one or more of citric acid, acetic acid, phosphoric acid, succinic acid, aspartic acid, glutamic acid and lactic acid;
the positively charged protein protectant is selected from one or more of arginine, lysine and histidine.
In some embodiments, the acid is citric acid.
In some embodiments, the positively charged protein protectant is arginine.
In some embodiments, the concentration of the acid is 5mM-50mM, preferably 5mM-35mM, more preferably 10mM-20mM; for example, 5mM-15mM, 5mM-10mM, 10mM-15mM, 8mM-12mM; in some embodiments, the concentration of the acid is about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 18mM, about 20mM, or any value in between; more preferably 5mM, 10mM or 20mM.
In some embodiments, the concentration of the positively charged protein protectant is 100mM-220mM, preferably 150mM-200mM, more preferably 150mM-170mM; for example, 100mM-200mM, 120mM-200mM, 140mM-180mM, 170mM-180mM; in some embodiments, the concentration of the positively charged protein protecting agent is about 150mM, about 160mM, about 170mM, about 180mM, about 190mM, about 140mM, about 145mM, about 165mM, about 175mM, or any value in between any two values; more preferably 150mM or 170mM.
In some embodiments, the antibody class drug is selected from one or more of an anti-human IL-17A monoclonal antibody, an anti-human HER2 monoclonal antibody, an anti-human TNF-a monoclonal antibody. In some specific embodiments, the antibody is an anti-human IL-17A monoclonal antibody comprising an amino acid sequence as set forth in SEQ ID NO:1 and a heavy chain as set forth in SEQ ID NO:2, and a light chain as shown in FIG. 2. In some specific embodiments, the antibody is secukinumab. In some specific embodiments, the antibody is an anti-human HER2 monoclonal antibody comprising the amino acid sequence as set forth in SEQ ID NO:3 and a heavy chain as set forth in SEQ ID NO: 4.
In some embodiments, the concentration of the antibody drug is 10-300mg/mL, preferably 10-250mg/mL, more preferably 30-250mg/mL, and most preferably 135-165mg/mL.
In some embodiments, the concentration of the antibody is 50mg/mL-200mg/mL, preferably 50mg/mL-60mg/mL or 90mg/mL-160mg/mL, more preferably 100mg/mL-150mg/mL. Such as 90mg/mL to 180mg/mL, 90mg/mL to 170mg/mL, 90mg/mL to 155mg/mL, 95mg/mL to 155mg/mL; in some embodiments, the concentration of the antibody is about 90mg/mL, about 95mg/mL, about 100mg/mL, about 140mg/mL, about 1450mg/mL, about 150mg/mL, about 160mg/mL, about 155mg/mL, or any value therebetween. Preferably 100mg/mL or 150mg/mL.
In some embodiments, the aforementioned antibody pharmaceutical compositions further comprise a surfactant.
In some embodiments, the surfactant is selected from polysorbate 20, polysorbate 80, and poloxamer 188. In some embodiments, the surfactant is at a concentration of 0.1mg/mL to 0.6mg/mL, e.g., 0.1mg/mL to 0.6mg/mL, 0.15mg/mL to 0.55mg/mL, 0.2mg/mL to 0.5mg/mL. Preferably 0.2mg/mL.
In some embodiments, the aforementioned antibody pharmaceutical composition further comprises an antioxidant.
In some embodiments, the antioxidant is selected from methionine, glutathione, cysteine, cystine, or ascorbic acid. In some embodiments, the antioxidant is at a concentration of 20mM-30mM, e.g., 20mM-28mM, 22mM-26mM; preferably 25mM.
In some embodiments, the pH of the aforementioned antibody pharmaceutical composition is from 5.6 to 6.0, e.g., from 5.7 to 6.0, from 5.8 to 6.0, from 5.6 to 5.9; in some specific embodiments, the pH of the antibody pharmaceutical composition is about 5.6, about 5.7, about 5.8, about 5.9, about 6.0; preferably 5.8.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 50mg/mL-200mg/mL of antibody;
b) 5mM-50mM acetic acid;
c) Arginine at 100mM-220 mM; and
d) 0.1mg/mL-0.6mg/mL polysorbate 80; wherein the pH of the antibody pharmaceutical composition is 5.6-6.0.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 50mg/mL-200mg/mL of antibody;
b) 5mM-50mM citric acid;
c) Arginine at 100mM-220 mM;
d) 0.1mg/mL-0.6mg/mL polysorbate 20; and
e) Methionine at 20mM-30 mM; wherein the pH of the antibody pharmaceutical composition is 5.6-6.0.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 90mg/mL-160mg/mL of antibody;
b) 5mM-35mM citric acid;
c) 150mM-200mM arginine;
d) 0.1mg/mL-0.6mg/mL polysorbate 20; and
e) Methionine at 20mM-30 mM; wherein the pH of the antibody pharmaceutical composition is 5.6-6.0.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 150mg/mL of antibody;
b) 10mM citric acid;
c) 150mM-170mM arginine;
d) 0.2mg/mL polysorbate 20; and
e) 25mM methionine; and the pH of the antibody pharmaceutical composition is 5.6-6.0.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 90mg/mL-160mg/mL of antibody;
b) 5mM-35mM citric acid;
c) 150mM-200mM arginine;
d) 0.1mg/mL-0.6mg/mL polysorbate 20; and
e) Methionine at 20mM-30 mM; wherein the pH of the antibody pharmaceutical composition is 5.6-6.0, and the antibody is an anti-human IL-17A monoclonal antibody, which comprises the amino acid sequence shown in SEQ ID NO:1 and a heavy chain as set forth in SEQ ID NO:2, and a light chain as shown in FIG. 2.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 150mg/mL of the antibody, and,
b) 10mM citric acid;
c) 150mM-170mM arginine;
d) 0.2mg/mL polysorbate 20; and
e) 25mM methionine; and the pH of the antibody pharmaceutical composition is 5.6-6.0, wherein the antibody is an anti-human IL-17A monoclonal antibody comprising the amino acid sequence as shown in SEQ ID NO:1 and a heavy chain as set forth in SEQ ID NO:2, and a light chain as shown in FIG. 2.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 150mg/mL of the antibody, and,
b) 10mM citric acid;
c) 150mM arginine;
d) 0.2mg/mL polysorbate 20; and
e) 25mM methionine; and the pH of the antibody pharmaceutical composition is 5.6-6.0, wherein the antibody is an anti-human IL-17A monoclonal antibody comprising the amino acid sequence as shown in SEQ ID NO:1 and a heavy chain as set forth in SEQ ID NO:2, and a light chain as shown in FIG. 2.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 150mg/mL of the antibody, and,
b) 10mM citric acid;
c) 170mM arginine;
d) 0.2mg/mL polysorbate 20; and
e) 25mM methionine; and the pH of the antibody pharmaceutical composition is 5.6-6.0, wherein the antibody is an anti-human IL-17A monoclonal antibody comprising the amino acid sequence as shown in SEQ ID NO:1 and a heavy chain as set forth in SEQ ID NO:2, and a light chain as shown in FIG. 2.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 50mg/mL-60mg/mL of antibody; wherein the antibody is an anti-human Her2 monoclonal antibody comprising the amino acid sequence as set forth in SEQ ID NO:3 and a heavy chain as set forth in SEQ ID NO:4, and a light chain represented by the formula 4
b) 10mM-20mM acetic acid;
c) 170mM-180mM arginine; and
d) 0.15mg/mL-0.55mg/mL polysorbate 80; wherein the pH of the antibody pharmaceutical composition is 5.6-6.0.
In some embodiments, the aforementioned antibody pharmaceutical composition comprises:
a) 50mg/mL of antibody; wherein the antibody is an anti-human Her2 monoclonal antibody comprising the amino acid sequence as set forth in SEQ ID NO:3 and a heavy chain as set forth in SEQ ID NO:4, and a light chain represented by the formula 4
b) 20mM acetic acid;
c) 175M arginine; and
d) 0.2mg/mL polysorbate 80; wherein the pH of the antibody pharmaceutical composition is 5.6-6.0.
In some embodiments, the aforementioned antibody drug combination has an osmolality ranging from 285 to 310mOsmol/kg and a viscosity of less than 7.2cp. Preferably, the viscosity is 2.5 to 6.9cP, 2.9 to 6.7cP, or 1.65 to 6.1cP. In some embodiments, the viscosity is 2.9cp, 6.1cp, or 6.7cp.
The osmotic pressure molar concentration range of normal human blood is 285-310 mOsmol/kg, the liquid preparation provides a medicine composition which is isotonic with human body, has better stability and lower viscosity, and is favorable for the administration of the liquid preparation by subcutaneous injection.
In some embodiments, the antibody pharmaceutical compositions of the invention are liquid formulations.
In another aspect, the invention provides a lyophilized formulation obtained by freeze-drying an antibody pharmaceutical composition according to any one of the preceding claims.
In a further aspect, the invention provides the use of an antibody pharmaceutical composition as defined in any preceding claim or a lyophilized formulation as defined above in the manufacture of a medicament for the treatment of a disease associated with IL-17A and/or IL-17F.
In some embodiments, the disease is selected from psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, osteoarthritis, and inflammatory bowel disease.
In the antibody pharmaceutical composition of the invention, negatively charged citric acid is combined with positively charged arginine (which is a basic amino acid, also known as an amino acid base) to maintain the pH of the liquid formulation.
In another aspect, the invention provides a method of preparing an antibody pharmaceutical composition of any of the preceding claims, the method comprising the step of replacing an antibody solution with a solution comprising a negatively charged buffer and a positively charged protein protectant, wherein:
the negatively charged buffer is an acid substantially free of its salt form, the acid being selected from one or more of citric acid, acetic acid, phosphoric acid, succinic acid, aspartic acid, glutamic acid and lactic acid; the positively charged protein protectant is selected from one or more of arginine, lysine and histidine.
In some embodiments, the invention provides a method of preparing an antibody pharmaceutical composition of any of the preceding claims, the method comprising the step of replacing the antibody solution with a solution comprising citric acid and arginine, or a solution of acetic acid and arginine.
In some embodiments, the method replaces the antibody solution with a solution comprising 5mM-50mM citric acid and 5mM-40mM arginine.
In some embodiments, the method replaces the antibody solution with a solution comprising 5mM-15mM citric acid and 9mM-30mM arginine.
In some embodiments, the method replaces the antibody solution with a solution comprising 5mM-15mM citric acid and 12mM-30mM arginine.
In some embodiments, the method replaces the antibody solution with a solution comprising 5mM-10mM citric acid and 12mM-24mM arginine.
In some embodiments, the method replaces the antibody solution with a solution comprising 10mM citric acid and 24mM arginine.
In some embodiments, the method replaces the antibody solution with a solution comprising 10mM acetic acid and 9.2mM arginine.
The present invention provides a method for preparing the antibody pharmaceutical composition of any one of the preceding claims, wherein the ultrafiltration step does not require additional adjustment of the pH of the antibody solution. In the liquid ultrafiltration liquid exchange process, the combination of citric acid and arginine is used as a replacement liquid. The liquid preparation has more excellent stability under the same osmotic pressure and lower viscosity.
The invention can provide more excellent antibody drug stability under the condition of the same osmotic pressure, and the viscosity of the liquid preparation under the condition of higher antibody concentration is lower.
In the invention, in the preparation with the same osmotic pressure in the preparation prescription development process, the combination of the acid without salt and the stabilizer with single positive charge is used, the usage amount of the stabilizer is more than that of other buffers (such as citric acid-sodium citrate buffer) containing salt, and the stabilizer with more usage amount is favorable for stabilizing the antibody and reducing the viscosity. Mechanically, the method comprises the following steps: the charged stabilizer has larger ionic strength, and is combined to the surface of the protein, so that electrostatic force repulsive force between the proteins is reduced or hydrophobic acting force between the proteins is reduced, and the purposes of stabilizing the antibody and reducing the viscosity are achieved.
The conception, specific structure, and technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, features, and effects of the present invention.
Drawings
Fig. 1 is a superposition of polymer peaks in SEC spectra of formulation 1 and formulation 2 at an elevated temperature of 14 days.
Fig. 2 is a superposition of IEC maps for formulation 1 and formulation 2 at high temperature for 7 days.
Fig. 3 is a superposition of RP spectra of formulation 1 and formulation 2 at high temperature for 14 days.
Detailed Description
The term "comprising" encompasses both the meaning of "comprising" and "consisting of … …", e.g. a composition "comprising" X may consist of X alone, as well as some other ingredients, e.g. x+y.
"composition" means a mixture comprising one or more of the compounds described herein or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to promote the administration to organisms, facilitate the absorption of active ingredients and thus exert biological activity. As used herein, "pharmaceutical composition," "formulation," and "prescription" are used interchangeably. The pharmaceutical compositions described herein are in the form of solutions, wherein the solvent is water unless otherwise specified.
"buffering agent" generally refers to a substance that is resistant to pH changes by the action of its acid-base conjugate components, and in the present invention, the buffering agent is an acid that is substantially free of its salt form, which interacts with a positively charged protein protectant to act as a buffer. In the present invention, a positively charged protein protectant (an amino acid base such as arginine) is combined with an acid that is substantially free of its salt form to maintain pH.
By "substantially free of an acid in its salt form" is meant that the acid, which acts as a buffer in the liquid pharmaceutical composition, is present in the absence of any salt form thereof. Acid-containing buffers commonly used in liquid pharmaceutical compositions are prepared with salts of the acids or a combination of the acids and salt forms thereof. Thus, for example, the buffer is prepared with an acid and its counter ion, such as sodium, potassium, ammonium, calcium or magnesium. Such a citric acid buffer typically contains a salt of citric acid, such as citric acid-sodium citrate. Acids suitable for use in formulating the stabilized polypeptide-containing liquid pharmaceutical compositions of the present invention include, but are not limited to, citric acid, acetic acid, phosphoric acid, succinic acid, aspartic acid, glutamic acid, and lactic acid, with citric acid being more preferred.
"positively charged protein protectant" refers to an "amino acid base" that is an amino acid or combination of amino acids, wherein any given amino acid is present in its free base form or in its salt form. Preferred amino acids for use in preparing the compositions of the present invention are amino acids with charged side chains, such as arginine.
Surfactants suitable for use in the compositions disclosed herein include, but are not limited to, nonionic surfactants, ionic surfactants, zwitterionic surfactants, and combinations thereof. Typical surfactants for use in the present invention include, but are not limited to, sorbitan fatty acid esters (e.g., sorbitan monocaprylate, sorbitan monolaurate, sorbitan monopalmitate), sorbitan trioleate, glycerol fatty acid esters (e.g., glycerol monocaprylate, glycerol monomyristate, glycerol monostearate), polyglycerol fatty acid esters (e.g., decaglyceryl monostearate, decaglyceryl distearate, decaglyceryl monolinoleate), polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan trioleate, polyoxyethylene sorbitan tristearate), polyoxyethylene sorbitol fatty acid esters (e.g., polyoxyethylene sorbitol tetrastearate, polyoxyethylene sorbitol tetraoleate), polyoxyethylene glycerol fatty acid esters (e.g., polyoxyethylene glyceryl monostearate), polyethylene glycol fatty acid esters (e.g., polyethylene glycol distearate), polyoxyethylene alkyl ethers (e.g., polyoxyethylene lauryl ether), polyoxyethylene polyoxypropylene alkyl ethers (e.g., polyoxyethylene polyoxypropylene glycol, polyoxyethylene polyoxypropylene propyl ether, polyoxyethylene polyoxypropylene cetyl ether), polyoxyethylene alkylphenyl ethers (e.g., polyoxyethylene nonylphenyl ether), polyoxyethylene castor oil (e.g., polyoxyethylene castor oil, hydrogenated castor oil), polyoxyethylene beeswax derivatives (e.g., polyoxyethylene sorbitol beeswax), polyoxyethylene lanolin derivatives (e.g., polyoxyethylene lanolin), and polyoxyethylene fatty acid amides (e.g., polyoxyethylene stearic acid amide); C10-C18 alkyl sulfates (e.g., sodium cetyl sulfate, sodium lauryl sulfate, sodium oleyl sulfate), polyoxyethylene C10-C18 alkyl ether sulfates having an average addition of 2 to 4 moles of ethylene oxide units (e.g., sodium polyoxyethylene lauryl sulfate), and C1-C18 alkyl sulfosuccinates (e.g., sodium lauryl sulfosuccinate salt); and natural surfactants such as lecithin, glycerophospholipids, sphingomyelins (e.g., sphingomyelins), and sucrose esters of C12-C18 fatty acids. The composition may comprise one or more of these surfactants. Preferred surfactants are polyoxyethylene sorbitan fatty acid esters, such as polysorbate 20, 40, 60 or 80. Polysorbate 20 (e.g., at a concentration of about 0.2 mg/mL) is particularly suitable.
By "lyophilized formulation" is meant a pharmaceutical composition or a formulation of a solution or a pharmaceutical composition obtained after a vacuum freeze-drying step of the pharmaceutical composition or the formulation of a solution in liquid or solution form.
The term "about" or "approximately" as used herein means that the value is within an acceptable error range for the particular value being determined by one of ordinary skill in the art, the value depending in part on how the measurement or determination is made (i.e., the limits of the measurement system). For example, "about" in each implementation in the art may mean within 1 or exceeding a standard deviation of 1. Alternatively, "about" or "substantially comprising" may mean a range of up to ±20%, e.g., a pH of about 5.5 means a pH of 5.5±1.1. Furthermore, the term may mean at most one order of magnitude or at most 5 times the value, especially for biological systems or processes. Unless otherwise indicated, when a particular value is found in this application and in the claims, the meaning of "about" or "consisting essentially of" should be assumed to be within the acceptable error range for that particular value.
The term "Fc region" or "fragment crystallizable region" is used to define the C-terminal region of the antibody heavy chain. In some embodiments, the Fc region of a human IgG heavy chain is defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxy terminus. Suitable native sequence Fc regions for antibodies described herein include human IgG1, igG2 (IgG 2A, igG 2B), igG3, and IgG4. The numbering convention for the Fc region is EU index, unless otherwise indicated. The C-terminus of the Fc region may be the complete C-terminus ending with the amino acid residue PGK, or may be a truncated C-terminus, e.g., with one or two C-terminal amino acid residues removed in the truncated C-terminus. Thus, in some embodiments, the composition of an intact antibody may include a population of antibodies that have all K447 residues and/or g446+k447 residues removed. In some embodiments, the composition of intact antibodies may include a population of antibodies that do not remove the K447 residue and/or the g446+k447 residue. In some embodiments, the composition of intact antibodies has an antibody population with and without a mixture of antibodies with the K447 residue and/or the g446+k447 residue. The pharmaceutical composition described herein is capable of achieving a stable effect: wherein the antibody substantially retains its physical and/or chemical stability and/or biological activity after storage, e.g., the pharmaceutical composition substantially retains its physical and chemical stability and its biological activity after storage. The shelf life is generally selected based on the predetermined shelf life of the pharmaceutical composition. There are a number of analytical techniques for measuring protein stability that measure stability after storage at a selected temperature for a selected period of time.
A stable pharmaceutical antibody formulation is one in which no significant change is observed in the following cases: preserving at refrigeration temperature (2-8deg.C) for at least 3 months, at least 6 months, at least 1 year, and up to 2 years. In addition, stable liquid formulations include those that: which exhibits the desired characteristics after a period of time including 1 month, 3 months, 6 months, or 1 month at 40 ℃ of storage at 25 ℃. Typical acceptable criteria for stability are as follows: typically no more than about 10%, e.g., no more than about 5%, of the antibody monomers degrade as measured by SEC-HPLC. The pharmaceutical antibody formulation was colorless, or clear to slightly milky, by visual analysis. The concentration, pH and osmolality of the formulation have a variation of no more than + -10%. It is generally observed that no more than about 10%, such as no more than about 5%, truncations, typically form no more than about 10%, such as no more than about 5%, of aggregates.
An antibody "retains its physical stability" in a pharmaceutical formulation if it does not exhibit a significant increase in aggregation, precipitation and/or denaturation after visual inspection of color and/or clarity, or as measured by UV light scattering, size Exclusion Chromatography (SEC) and Dynamic Light Scattering (DLS). The change in protein conformation can be assessed by fluorescence spectroscopy (which determines the tertiary structure of the protein) and by FTIR spectroscopy (which determines the secondary structure of the protein).
An antibody "retains its chemical stability" in a pharmaceutical formulation if it does not exhibit a significant chemical change. Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein. Degradation processes that often alter the chemical structure of proteins include hydrolysis or truncation (assessed by methods such as size exclusion chromatography and SDS-PAGE), oxidation (assessed by methods such as peptide spectroscopy in combination with mass spectrometry or MALDI/TOF/MS), deamidation (assessed by methods such as ion exchange chromatography, capillary isoelectric focusing, peptide spectroscopy, isoaspartic acid measurement, etc.), and isomerization (assessed by measuring isoaspartic acid content, peptide spectroscopy, etc.).
An antibody "retains its biological activity" in a pharmaceutical formulation if the biological activity of the antibody at a given time is within a predetermined range of biological activities exhibited when the pharmaceutical formulation is prepared. The biological activity of an antibody may be determined, for example, by an antigen binding assay.
In this context, unless otherwise indicated or clearly unsuitable, proportions, including percentages, are by weight.
Herein, "/" means either not contained or not detected.
"administration" and "treatment" when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid refers to the contact of an exogenous drug, therapeutic, diagnostic, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid. "administration" and "treatment" may refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Treatment of a cell includes contacting a reagent with the cell, and contacting the reagent with a fluid, wherein the fluid is in contact with the cell. "administration" and "treatment" also mean in vitro and ex vivo treatment of, for example, a cell by an agent, diagnosis, binding composition, or by another cell. "treatment" when applied to a human, veterinary or research subject refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.
By "treating" is meant administering to a subject an internally or externally used therapeutic agent, such as a composition comprising any of the binding compounds disclosed herein, that has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of the disease in the subject or population being treated to induce regression of such symptoms or to inhibit the development of such symptoms to any clinically measurable extent. The amount of therapeutic agent (also referred to as a "therapeutically effective amount") effective to alleviate any particular disease symptom can vary depending on a variety of factors, such as the disease state, age, and weight of the subject, and the ability of the drug to produce a desired therapeutic effect in the subject. Whether a disease symptom has been reduced can be assessed by any clinical test method that a physician or other healthcare professional typically uses to assess the severity or progression of the symptom. Although embodiments (e.g., methods of treatment or articles of manufacture) disclosed herein may be ineffective in alleviating each symptom of the target disease, they should alleviate the symptom of the target disease in a statistically significant number of subjects, as determined by any statistical test methods known in the art, such as Student t-test, chi-square test, U-test according to Mann and Whitney, kruskal-Wallis test (H test), jonckheere-Terpstra test, and Wilcoxon test.
An "effective amount" comprises an amount sufficient to ameliorate or prevent a symptom or condition of a medical disorder. An effective amount is also meant to be an amount sufficient to permit or facilitate diagnosis. The effective amount for a particular subject or veterinary subject may vary depending on the following factors: for example, the condition to be treated, the general health of the subject, the route and dosage of administration, and the severity of the side effects. An effective amount may be the maximum dose or regimen that avoids significant side effects or toxic effects.
The invention is further described with reference to the following detailed description in order to make the technical means, the inventive features, the achieved objects and the effects of the invention easy to understand. The present invention is not limited to the following examples.
The detection method used in the embodiment of the application comprises the following steps:
SEC detection:
the instrument is an Agilent 1260 mixed module liquid chromatography system; analytical column TSKgel G3000SW XL 7.8X100 mm; mobile phase is 0.15mol/L phosphate, ph=6.5; the flow rate is 0.4ml/min; column temperature is 30 ℃; the detection wavelength is 220nm; the running time is equal gradient running for 40min.
IEC detection:
the instrument is an Agilent 1260 mixed module liquid chromatography system; the analytical column is Thermo ProPac TM WCX-104X 250mm; mobile phase a was 0.025mol/L sodium dihydrogen phosphate-sodium hydroxide, ph=6.0, mobile phase B was 0.025mol/L sodium dihydrogen phosphate-sodium hydroxide, 0.25mol/L sodium chloride, ph=6.0; the flow rate is 1.0ml/min; the detection wavelength is 220nm; column temperature 25 ℃; the run time was 40min and the run gradient is shown in table 1.
TABLE 1 gradient of mobile phase elution
Time (min) | Mobile phase a (%) | Mobile phase B (%) |
0 | 90 | 10 |
30.0 | 63 | 37 |
30.1 | 0 | 100 |
32.0 | 0 | 100 |
32.1 | 90 | 10 |
40.0 | 90 | 10 |
RP detection:
the instrument is an Agilent 1260 mixed module liquid chromatography system; the analytical column was Agilent 300SB-C8, 4.6X105 mm,5 μm; mobile phase a is 0.1% aqueous trifluoroacetic acid and mobile phase B is 0.1% acetonitrile trifluoroacetic acid; the flow rate is 1.0ml/min; the detection wavelength is 280nm; column temperature 80 ℃; the run time was 50min and the run gradient is shown in table 2.
TABLE 2 gradient of mobile phase elution
Time (min) | Mobile phase a (%) | Mobile phase B (%) |
0 | 75 | 25 |
4.0 | 75 | 25 |
35.0 | 58 | 42 |
37.0 | 75 | 25 |
40.0 | 5 | 95 |
42.0 | 75 | 25 |
50.0 | 75 | 25 |
CE detection:
the instrument is an Agilent 7100 capillary electrophoresis apparatus; the effective length of the capillary tube is 220mm, and the total length is 305mm; -10.0kv sample introduction for 40s; operating voltage-15.0 kv; running for 40min; detection wavelength 214nm; column temperature 20 ℃.
The anti-human IL-17A monoclonal antibody used in the invention is Stuzumab, and the sequence of the anti-human IL-17A monoclonal antibody is as follows:
heavy chain of secukinumab (SEQ ID NO: 1):
light chain of Stuzumab (SEQ ID NO: 2):
example 1 formulation recipe and preparation
1.1. Preparation of formulation 1
Formulation 1 was a stock solution of Studies consisting of 150mg/ml anti-human IL-17A monoclonal antibody, 20mM histidine-HCl, 200mM trehalose, 5mM methionine, 0.2mg/ml polysorbate 80, pH5.8. The solvent was water and the pH was adjusted with hydrochloric acid.
The preparation process comprises the following steps: the purified anti-human IL-17A monoclonal antibody is ultrafiltered and concentrated to 50-80 mg/ml, and a 20mM histidine-histidine hydrochloride buffer system is used for ultrafiltering and replacing 6-15 times of volume, and then ultrafiltering and concentrating is carried out to 175-215 mg/ml to obtain concentrated solution. Adding the prepared first buffer solution (which needs to be confirmed by calculation) for dilution into the concentrated solution, uniformly mixing and filtering to obtain the anti-human IL-17A monoclonal antibody protein stock solution with the concentration of 150mg/ml, and then filling to obtain the preparation 1.
The 20mM histidine-histidine hydrochloride buffer system was 20mM histidine and the pH was adjusted to 5.6 with hydrochloric acid.
The first buffer for dilution contains histidine, trehalose, methionine and polysorbate 80. Because of the difference in concentration of the concentrates, it is necessary to calculate to formulate and add the first buffer for dilution, thereby obtaining formulation 1 as described above.
1.2. Preparation of formulation 2
Formulation 2 consisted of 150mg/ml anti-human IL-17A monoclonal antibody, 10mM citric acid, 150mM arginine, 25mM methionine, 0.2mg/ml polysorbate 20, pH5.8. The solvent is water, and the pH is adjusted by citric acid.
The preparation process comprises the following steps: the purified anti-human IL-17A monoclonal antibody is ultrafiltered and concentrated to 50-80 mg/ml, 10mM citric acid and 24mM arginine buffer system is used for ultrafiltering and replacing 6-15 times of volume, and then ultrafiltering and concentrating is carried out to 175-215 mg/ml to obtain concentrated solution. Adding a prepared second buffer solution (comprising citric acid, arginine, methionine and polysorbate 20, wherein the concentration of each component is required to be confirmed through calculation) for dilution into the concentrated solution, uniformly mixing and filtering to obtain an anti-human IL-17A monoclonal antibody protein stock solution with the concentration of 150mg/ml, and then filling to obtain the preparation 2.
The 10mM citric acid+24 mM arginine buffer system was an aqueous solution containing 10mM citric acid and 24mM arginine at a pH of 5.6 (without additional pH adjustment).
The second buffer for dilution contains citric acid, arginine, methionine and polysorbate 20. Because of the difference in concentration of the concentrates, it was calculated to formulate and add the second buffer for dilution to obtain formulation 2 as described above.
Example 2: comparison of Properties of formulation 1 and formulation 2
The measurement was carried out using a freezing point depression osmometer (2020 edition "Chinese pharmacopoeia general rule" 0632) and a pressure-driven microaerometer (U.S. pharmacopoeia <914> viscosity-pressure-driven method).
The results show that: formulation 1 had an osmotic pressure of 306mOsmol/kg and a viscosity of 7.2cP; formulation 2 had an osmotic pressure of 302mOsmol/kg and a viscosity of 6.1cP.
As can be seen from comparison of the osmolalities of preparation 1 and preparation 2, both were within the osmolality range of normal human blood (285-310 mOsmol/kg). The low viscosity preparation is easier to carry out the production process (lower shearing force when using peristaltic pump, lower back pressure when using membrane filtration and difficult to block) in the production process, and is more beneficial to self injection of patients (tissue back pressure and injection pain can be generated due to the excessive viscosity). Thus, formulation 2 is easier to manufacture due to its lower viscosity and is more beneficial for administration via the subcutaneous route (reduced injection pain) than formulation 1.
The main peak of formulation 2 (i.e., anti-human IL-17A monoclonal antibody) was found to be of higher purity and the polymer and fragment peaks were lower under the various treatment conditions shown in table 3, as measured by Size Exclusion Chromatography (SEC), ion Exchange Chromatography (IEC), reverse phase chromatography (RP) and capillary electrophoresis Chromatography (CE), indicating that formulation 2 had more excellent stability (see table 4, fig. 1-3). As can be seen from fig. 1, the peak of the polymer of formulation 2 is lower than that of formulation 1, indicating that formulation 2 has fewer polymers than formulation 1, and formulation 2 is safer and more stable. As can be seen in FIGS. 2 and 3, the main peak of preparation 2 is significantly higher than that of preparation 1, indicating that the purity of the anti-human IL-17A monoclonal antibody in preparation 2 is higher.
TABLE 3 multiple processing scenarios
Table 4 comparison of stability of formulations 1 and 2 under various treatment conditions
/>
Note that: N/A indicates no detection and no data.
Example 3 Effect of different buffers on the stability of Stuzumab
As shown in table 5, the following formulations were prepared:
TABLE 5 preparations 5-7
Note that: citric acid-sodium citrate: after weighing the citric acid formulation, the pH was adjusted using sodium hydroxide, and the buffer was defined as a citric acid-sodium citrate buffer.
The preparation process of the preparation 5 comprises the following steps: ultrafiltering and concentrating the purified anti-human IL-17A monoclonal antibody to obtain the final product
50-80 mg/ml, ultrafiltration and displacement by using a 10mM citric acid+24 mM arginine buffer system for 6-15 times of volume, and ultrafiltration concentration to reduce the concentration of the antibody to 175-215 mg/ml to obtain concentrated solution. Adding a prepared second buffer solution (containing citric acid, arginine, methionine and polysorbate 20, wherein the concentration of each component is required to be confirmed through calculation) for dilution into the concentrated solution, uniformly mixing and filtering to obtain an anti-human IL-17A monoclonal antibody protein stock solution with the concentration of 150mg/ml, and then filling to obtain the preparation 5. The viscosity of the preparation 5 is 6.7cp, and the osmotic pressure meets the requirement. Preparation 6 and preparation 7 are prepared by a similar process to preparation 5, and will not be described again here, except that the final components and proportions are shown in table 5.
The formulations were subjected to shaking, high temperature and freeze thawing (see table 3 for processing conditions) and the effect of different formulation formulations on the stability of secukinumab under different conditions, including Size Exclusion Chromatography (SEC), ion Exchange Chromatography (IEC) and capillary electrophoresis Chromatography (CE), results are given in table 6 below.
TABLE 6 stability analysis results for formulations 5-7
/>
The results show that:
preparation 5 had a higher purity of the main peak at each test item, especially after 10 days of light treatment. The peak of the polymer in SEC test for formulation 5 was significantly lower compared to formulations 6 and 7, while the main peak was higher; in IEC tests, the main peak height is higher, while the acidic and basic peaks are lower; in CE testing, the fragment peaks and the polymers were lower in height, while the main peaks were more prominent. These results indicate that citric acid buffer can better maintain the stability of the secukinumab than citrate buffer, and formulation 5 has significant advantages in terms of safety and stability.
Example 4 Effect of buffer concentration on formulation stability
To further examine whether the concentration of citric acid buffer would affect the stability of secukinumab, formulation 8 was prepared, which contained the following components: 100mg/mL of Stuzumab, 20mM citric acid, 200mM arginine, 0.5mg/mL polysorbate 80, pH6.0.
The preparation process comprises the following steps: the purified anti-human IL-17A monoclonal antibody is ultrafiltered and concentrated to 50-80 mg/ml, 10mM citric acid and 24mM arginine buffer system is used for ultrafiltering and replacing 6-15 times of volume, and then ultrafiltering and concentrating is carried out to 175-215 mg/ml to obtain concentrated solution. Adding the prepared second buffer solution (which needs to be confirmed by calculation) for dilution into the concentrated solution, uniformly mixing and filtering to obtain the anti-human IL-17A monoclonal antibody protein stock solution with the concentration of 100mg/ml, and then filling to obtain the preparation 8.
The osmotic pressure of formulation 8 was measured to be 298mOsm/kg and the viscosity was measured to be 2.9cP.
Formulation 8 was subjected to shaking, high temperature and freeze thawing (see table 3 for treatment conditions) and the effect of different formulation formulations on the stability of secukinumab under different conditions, including Size Exclusion Chromatography (SEC), ion Exchange Chromatography (IEC) and capillary electrophoresis Chromatography (CE), results are shown in table 7.
TABLE 7 comparison of stability of formulation 8 under various treatment conditions
/>
The results show that formulation 8 shows excellent stability under various conditions, demonstrating that 20mM citric acid can well maintain stability of the secukinumab.
Example 5: preparation of anti-human HER2 monoclonal antibody preparation 3 and preparation 4
Formulation 3 consisted of 50mg/ml anti-human HER2 monoclonal antibody (amino acid sequence see U.S. Pat. No. 3, 5821337A, SEQ ID NO:4 of the present invention), 20mM acetic acid, 235mM sucrose, 0.2mg/ml polysorbate 80, pH6.0. The solvent was water and the pH was adjusted with sodium hydroxide.
The anti-human HER2 monoclonal antibody is trastuzumab, which has the sequence:
trastuzumab heavy chain (SEQ ID NO: 3):
trastuzumab light chain (SEQ ID NO: 4):
/>
the preparation process comprises the following steps: the purified anti-human HER2 monoclonal antibody is ultrafiltered and concentrated to 20-30 mg/ml, the volume of the purified anti-human HER2 monoclonal antibody is ultrafiltered and replaced by 8-12 times by using a 10mM acetic acid-sodium hydroxide buffer system, and then the purified anti-human HER2 monoclonal antibody is ultrafiltered and concentrated to 80-120 mg/ml to obtain concentrated solution. And adding the prepared third buffer solution (which needs to be confirmed by calculation) for dilution into the concentrated solution, uniformly mixing and filtering to obtain 50mg/ml of anti-human HER2 monoclonal antibody protein stock solution, and then filling to obtain the preparation 3.
The 10mM acetic acid-sodium hydroxide buffer system was an aqueous solution containing 10mM acetic acid and adjusted to pH5.8 with sodium hydroxide.
The third buffer for dilution contains acetic acid, sucrose and polysorbate 80. Because of the difference in concentration of the concentrates, it was calculated to formulate and add the third buffer for dilution to obtain formulation 3 as described above.
Formulation 4 consisted of 50mg/ml anti-human HER2 monoclonal antibody (amino acid sequence see U.S. Pat. No. 3, 5821337A, SEQ ID NO. 4 of the present invention), 20mM acetic acid, 175mM arginine, 0.2mg/ml polysorbate 80, pH6.0. The solvent is water and acetic acid is used to adjust the pH.
The preparation process comprises the following steps: the purified anti-human HER2 monoclonal antibody is ultrafiltered and concentrated to 20-30 mg/ml, and the volume of the purified anti-human HER2 monoclonal antibody is ultrafiltered and replaced by 8-12 times by using a 10mM acetic acid+9.2 mM arginine buffer system, and then the purified anti-human HER2 monoclonal antibody is ultrafiltered and concentrated to 80-120 mg/ml to obtain concentrated solution. And adding the prepared fourth buffer solution (which needs to be confirmed by calculation) for dilution into the concentrated solution, uniformly mixing and filtering to obtain 50mg/ml of anti-human HER2 monoclonal antibody protein stock solution, and then filling to obtain the preparation 4.
The 10mM acetic acid-arginine buffer system was an aqueous solution containing 10mM acetic acid and 9.2mM arginine, at which point the pH was 5.8 (no additional pH adjustment was required).
The fourth buffer for dilution contains acetic acid, arginine and polysorbate 80. Because of the difference in concentration of the concentrates, it was calculated to formulate and add the fourth buffer for dilution to obtain formulation 4 as described above.
Example 6: comparison of Properties of formulation 3 and formulation 4
Formulation 3 is a prior art formulation and formulation 4 is a formulation of the present invention. Detection is carried out by using an osmometer and a micro-viscosimeter, and the detection is carried out by: formulation 3 had an osmotic pressure of 326mOsmol/kg and a viscosity of 1.91cP; the osmotic pressure of formulation 4 was 312mOsmol/kg and the viscosity was 1.65cP.
As can be seen from comparison of the osmolalities of formulations 3 and 4, both were within the ideal osmolality range (300.+ -.30 mOsmol/kg). The low viscosity preparation is easier to carry out the production process (lower shearing force when using peristaltic pump, lower back pressure when using membrane filtration and difficult to block) in the production process, and is more beneficial to self injection of patients (tissue back pressure and injection pain can be generated due to the excessive viscosity). Thus, formulation 4 is easier to manufacture due to its lower viscosity and is more beneficial for administration via the subcutaneous route (reduced injection pain) than formulation 3.
The main peak of formulation 4 (i.e., anti-human HER2 monoclonal antibody) was found to be higher in purity and lower in the polymer peak (see table 8) under the various treatment conditions shown in table 3, indicating that formulation 4 had more excellent stability.
TABLE 8 comparison of stability of formulations 3 and 4 under various treatment conditions
Note that: N/A indicates no detection and no data.
The foregoing describes in detail preferred embodiments of the present invention. It should be understood that numerous modifications and variations can be made in accordance with the concepts of the invention without requiring creative effort by one of ordinary skill in the art. Therefore, all technical solutions which can be obtained by logic analysis, reasoning or limited experiments based on the prior art by the person skilled in the art according to the inventive concept shall be within the scope of protection defined by the claims.
Claims (10)
1. An antibody pharmaceutical composition comprising a negatively charged buffer, a positively charged protein protectant, and an antibody, wherein:
the negatively charged buffer is an acid substantially free of its salt form, the acid being selected from one or more of citric acid, acetic acid, phosphoric acid, succinic acid, aspartic acid, glutamic acid and lactic acid;
the positively charged protein protectant is selected from one or more of arginine, lysine and histidine.
2. The antibody pharmaceutical composition of claim 1, wherein:
the concentration of the acid is 5mM-50mM, preferably 5mM-35mM, more preferably 10mM-20mM;
the concentration of the positively charged protein protecting agent is 100mM-220mM, preferably 150mM-200mM, more preferably 150mM-170mM; and/or
The antibody is selected from one or more of an anti-human IL-17A monoclonal antibody, an anti-human HER2 monoclonal antibody and an anti-human TNF-alpha monoclonal antibody; preferably, the antibody is an anti-human IL-17A monoclonal antibody comprising the amino acid sequence as set forth in SEQ ID NO:1 and a heavy chain as set forth in SEQ ID NO:2, and a light chain as shown in FIG. 2.
3. The antibody pharmaceutical composition of claim 1 or 2, wherein the concentration of the antibody is 50mg/mL to 200mg/mL, preferably 90mg/mL to 160mg/mL, more preferably 100mg/mL to 150mg/mL.
4. The antibody pharmaceutical composition of any one of claims 1-3, further comprising a surfactant selected from polysorbate 20, polysorbate 80, and poloxamer 188; preferably, the concentration of the surfactant is from 0.1mg/mL to 0.6mg/mL, preferably 0.2mg/mL.
5. The antibody pharmaceutical composition of any one of claims 1-4, further comprising an antioxidant selected from methionine, glutathione, cysteine, cystine, and ascorbic acid; preferably, the concentration of the antioxidant is 20mM-30mM, preferably 25mM.
6. The antibody pharmaceutical composition of any one of claims 1 to 5, wherein the pH of the antibody pharmaceutical composition is 5.6-6.0, preferably 5.8.
7. The antibody pharmaceutical composition of any one of claims 1-6 comprising:
a) 90mg/mL-160mg/mL of antibody;
b) 5mM-35mM citric acid;
c) 150mM-200mM arginine;
d) 0.1mg/mL-0.6mg/mL polysorbate 20; and
e) Methionine at 20mM-30 mM; wherein the pH of the antibody pharmaceutical composition is 5.6-6.0; preferably, the antibody pharmaceutical composition comprises:
a) 150mg/mL of antibody;
b) 10mM citric acid;
c) 150mM-170mM arginine;
d) 0.2mg/mL polysorbate 20; and
e) 25mM methionine; and the pH of the antibody pharmaceutical composition is 5.6-6.0.
8. The antibody pharmaceutical composition of any one of claims 1-7, wherein the pharmaceutical combination has an osmolality in the range of 285-310 mOsmol/kg and a viscosity of less than 7.2cp; preferably, the viscosity is 1.65cP-6.1cP.
9. A lyophilized formulation obtained by freeze-drying the antibody pharmaceutical composition of any one of claims 1-8.
10. Use of an antibody pharmaceutical composition according to any one of claims 1-8 or a lyophilized formulation according to claim 9 in the manufacture of a medicament for the treatment of a disease associated with IL-17A and/or IL-17F; preferably, the disease is selected from psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, osteoarthritis and inflammatory bowel disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211726084 | 2022-12-30 | ||
CN2022117260848 | 2022-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117838854A true CN117838854A (en) | 2024-04-09 |
Family
ID=90533898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311817823.9A Pending CN117838854A (en) | 2022-12-30 | 2023-12-27 | Stabilizer composition of antibody medicine and pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117838854A (en) |
-
2023
- 2023-12-27 CN CN202311817823.9A patent/CN117838854A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
EP4065161A1 (en) | High concentration formulations of anti-csf1 and anti-csf1r antibodies | |
AU2017225236B2 (en) | A lyophilised pharmaceutical formulation and its use | |
EP3288536B1 (en) | Compositions comprising anakinra | |
CN107205925B (en) | Liquid pharmaceutical composition | |
US20200190179A1 (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
CN117838854A (en) | Stabilizer composition of antibody medicine and pharmaceutical composition | |
WO2017164349A1 (en) | Medicinal composition comprising peg anti-human ngf antibody fab' fragment | |
EP3909607A1 (en) | Pharmaceutical composition comprising antibody, device comprising same, and use thereof | |
JP6445169B2 (en) | Stable benzyl alcohol-free aqueous solution containing α-type interferon | |
TWI771335B (en) | Stable pharmaceutical formulation | |
CN117257936A (en) | Adalimumab composition | |
CN114652825A (en) | Stable antibody preparation, preparation method and application thereof | |
CN116172947A (en) | Pharmaceutical composition containing bispecific antibody specifically binding VEGF and ANG2 | |
WO2020089743A1 (en) | Pharmaceutical composition of pegylated l-asparaginase | |
EA041785B1 (en) | PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING | |
EA040788B1 (en) | LIQUID COMPOSITION CONTAINING GM-CSF NEUTRALIZING COMPOUND | |
OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |